Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 59 HER2-positive Breast Cancer 14 Carcinoma, Non-Small-Cell Lung 5 Breast Diseases 4 Brain Neoplasms 3 Triple Negative Breast Neoplasms 2 Salivary Gland Neoplasms 2 HER2-positive Metastatic Breast Cancer 2 Colorectal Neoplasms 2 Breast Cancer Invasive 2 Breast Cancer Female 2 Advanced Breast Cancer 2 Stomach Neoplasms 1 Solid Tumor 1 Rare Tumour 1 Rare Tumor 1 Pathologic Complete Response 1 Neoplasm Metastasis 1 Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1 Lung Neoplasms 1 Locally Advanced Breast Cancer 1 HER2-positive Early Breast Cancer 1 HER2-positive Advanced Breast Cancer 1 HER2+ Early or Locally Advanced Breast Cancer 1 HER2+ Breast Cancer 1 HER2 Positive Breast Cancer 1 HER2 Insertion Mutation Positive Advanced NSCLC 1 HER-2 Positive Colorectal Cancer 1 Estrogen Receptor-positive Breast Cancer 1 Esophageal Squamous Cell Carcinoma 1

Interventions

pertuzumab 2 Trastuzumab 2 Carboplatin 2 pyrotinib 1 Taxes 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × HER2-positive Early Breast Cancer × pyrotinib × Clear all

NCT07340398 2026-01-21

TAYLOR

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Recruiting

HER2-positive Early Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡